H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Strata Skin Sciences Inc (NASDAQ: SSKN) today and set a price target of $3. The company’s shares opened today at $1.94.
Pantginis noted:
“Valuation and risks to price target achievement. We maintain our Buy rating and $3 price target. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, XTRAC, and project upside from: (1) increase in patients treated for lead indication psoriasis; and (2) increasing traction for XTRAC in its other approved indications, vitiligo and eczema/atopic dermatitis. This model allows us to flex multiple assumptions affecting a drug or device’s potential commercial profile.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.9% and a 32.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Strata Skin Sciences Inc is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.81 and a one-year low of $1.06. Currently, Strata Skin Sciences Inc has an average volume of 267.9K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SSKN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STRATA Skin Sciences, Inc. is a medical technology company, which engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
